The need for new therapies to treat coronavirus patients has prompted an onslaught of advisories from FDA clarifying how sponsors should assess and implement changes necessary to fit this new reality.
Jill Wechsler
Advertisement
Jill Wechsler is ACT's Washington Editor
Articles by Jill Wechsler
February 09, 2017
Advertisement
Latest Updated Articles
- PDUFA Offers New Tools to Support Drug Development & Review
February 9th 2017
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: IntraGel & UroGen Sign Collaboration & Investment Agreements, Lupin & Tenpoint Form Commercialization Collaboration
2
Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly
3
Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb
4
When Drug Pricing Becomes Trade Policy
5